

Iclusig[®] REMS

FDA REQUIRED REMS SAFETY INFORMATION

Iclusig[®] (ponatinib)

- Revised indications
- New safety information about risk of vascular occlusion
- New dosing considerations

<Date>

<Name, MD>

<Address>

<City, State, Zip>

<Dear Dr. NAME:>

IMPORTANT SAFETY UPDATE

The FDA has required ARIAD Pharmaceuticals, Inc., to distribute this update to the [\[Professional Organization\]](#) as part of their Iclusig REMS (Risk Evaluation and Mitigation Strategy) program. We request that you inform your members about the following **labeling updates** and **serious risks of Iclusig**:

• **Revised indications have been limited to:**

- Treatment of adult patients with T315I-positive chronic myeloid leukemia (CML) (chronic phase, accelerated phase, or blast phase) or T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)
- Treatment of adult patients with chronic phase, accelerated phase, or blast phase CML or Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated

• **New safety information about risk of vascular occlusion in Boxed Warning**

- Arterial and venous thrombosis and occlusions have occurred in at least **27%** of Iclusig clinical trial patients

• **New dosing considerations**


- **Optimal dosing has not been identified.** In clinical trials, the starting dose of Iclusig was 45 mg administered orally once daily. However, 59% of the patients required dose reductions to 30 mg or 15 mg once daily during the course of therapy

Iclusig[®] REMS

A nonpromotional fact sheet, reviewed by the FDA, with more detailed safety information is enclosed, and also available at: www.iclusigREMS.com/factsheet.pdf

This letter does not contain the complete safety profile for Iclusig[®] (ponatinib). Please visit www.iclusigREMS.com for more information.

Sincerely,



Frank G. Haluska, MD, PhD
Chief Medical Officer
Senior Vice President, Clinical Research and Development
ARIAD Pharmaceuticals, Inc.